Research roundup

Here are 3 research projects to watch in Houston

From CBD treatment for man's best friend to smart tech for senior living, here are three research projects coming out of the Bayou City. Getty Images

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston.

In InnovationMap's latest roundup of research projects, we look into studies on traffic-reducing technology, recently funded projects on senior living devices, and the effect of CBD oil on four-legged arthritis patients.

University of Houston researchers look into tech to solve traffic jams

Photo via uh.edu

Traffic in major cities including Houston has been a growing problem β€” especially as populations grow. But, when considering ways to alleviate the issue, University of Houston researchers found that technology β€” 511 traffic information systems and roadside cameras to traffic apps like Waze and Google Maps – is already helping the situation.

"Technology has the potential to help society, and one way is to help us make better infrastructure decisions and put less pressure on roads," says Paul A. Pavlou, dean of the C.T. Bauer College of Business and author for the report, in a UH news release.

Pavlou, whose report was published by Information Systems Research, and colleagues Aaron Cheng of the London School of Economics and Min-Seok Pang of Temple University discovered that Intelligent Transportation Systems, or ITS, saved cities using the technology more than $4.7 billion a year in lost work or productivity, 175 million hours a year in travel time, 53 million gallons a year in fossil fuel consumption, and 10 billion pounds less CO2 emitted each year, according to the release.

Houston, for instance, has yet to adopt a 511 traveler information system, but has worked with private companies to design and build intelligent transportation systems.

"Traffic is even worse than before since people move where the roads are built and drive more," Pavlou says. "The city is growing, but there are alternative ways that do not impose some much demand on roads with the intelligent use of technology in parallel."

Baylor College of Medicine's CBD research on canine arthritis

Photo via bcm.edu

Just like mankind, man's best friend is subject to arthritis. A study from Baylor College of Medicine in collaboration with Medterra CBD is looking into how cannabidiol, or CBD, can improve conditions in arthritis patients of both species.

The study was published in the journal PAIN and found that CBD treatment improved the quality of life for the dogs with artritis.

"CBD is rapidly increasing in popularity due to its anecdotal health benefits for a variety of conditions, from reducing anxiety to helping with movement disorders," says corresponding author Dr. Matthew Halpert, research faculty in the Department of Pathology and Immunology at Baylor, in a news release. "In 2019, Medterra CBD approached Baylor to conduct independent scientific studies to determine the biological capabilities of several of its products."

Arthritis is a common condition in dogs, with the American Kennel Club finding that it affects around 20 percent of dogs in the United States. Plus, according to the release, the dogs' conditions are similar to humans.

"We studied dogs because experimental evidence shows that spontaneous models of arthritis, particularly in domesticated canine models, are more appropriate for assessing human arthritis pain treatments than other animal models. The biological characteristics of arthritis in dogs closely resemble those of the human condition," Halpert says.

According to Halpert, the study found good results. Nine of the 10 dogs on CBD showed benefits, he says.

Rice University's senior living tech receives grants

Photo via rice.edu

Rice University researchers who are looking into technology that can advance senior living facilities have received three new grants to continue their study.

According to a press release from Rice, the Internet of Things and Aging-in-Place Seed Grants, which is funded by Rice ENRICH and UTHealth, support research teams that "work together to test ideas, gather critical information and lay the groundwork for larger grant applications in the future."

"The Rice ENRICH office serves to facilitate collaborations of Rice faculty with those at TMC (Texas Medical Center) institutions," says Marcia O'Malley, a professor of mechanical engineering at Rice and an adviser to the provost for Rice ENRICH, in the release. "Our recent engagement with UTHealth and the seed funds awarded demonstrates Rice's commitment to building lasting relationships in the TMC community."

The grants were awarded to three projects:

  1. "Aging in Place with Cognitive Impairment: Toward User-Centered Assistive Technologies. " This study will look into availability and usefulness of assistive technologies among white, Hispanic, and African American patients with mild cognitive impairment to moderate dementia.
  2. "Facial and Body Motion Technology to Detect Psychosocial Distress in Stroke Survivors and Informal Caregivers Living at Home." This study will look at stroke survivors and their informal caregivers to help test technologies in a simulated home environment and look for signs of psychosocial distress, which can contribute to poor health outcomes.
  3. "An AI-powered chatbot for supporting the medication information needs of older adults." β€”This study will develop a voice-activated system that could be integrated into smart assistants to answer medication-related questions.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News